Skip to main content
Download PDF

Mortality and exacerbations associated with Stenotrophomonas maltophilia in chronic obstructive pulmonary disease. A regional cohort study of 22,689 outpatients

Respiratory Research volume 24, Article number: 232 (2023) Cite this article

Abstract

Objectives

The clinical significance of Stenotrophomonas maltophilia in patients with COPD is poorly understood. We aimed to determine whether a lower respiratory tract culture positive for S. maltophilia in COPD patients was independently associated with increased risk of death and hospitalisation for exacerbation of COPD.

Methods

An observational cohort study following outpatients with COPD in Eastern Denmark between 2010 and 2018, with a follow-up period of five years. Presence of S. maltophilia was treated as a time-varying exposure, where patients were considered exposed at the time of the first isolation of S. maltophilia from the lower respiratory tract. The hazard ratio (HR) of death and hospitalisation for acute exacerbations of COPD was assessed using a Cox proportional hazards regression.

Results

Of the total 22,689 patients 459 (2.0%) had a lower respiratory sample positive for S. maltophilia. A total of 7,649 deaths (S. maltophilia positive: 243 (52.9%) and S. maltophilia negative: 7,406 (34.4%)) and 24,912 hospitalisations for exacerbation of COPD (S. maltophilia positive: 1,100 in 459 patients and S. maltophilia negative: 23,821 in 22,230 patients) were registered during the study period. We found that a lower respiratory tract culture positive for S. maltophilia was associated with both increased mortality: HR 3.3 (95% CI 2.6–4.3), and hospitalisation for exacerbation of COPD: HR 3.4 (95% CI 2.8–4.1).

Conclusions

A lower respiratory tract culture positive for S. maltophilia in COPD patients was associated with a substantially increased mortality and hospitalisation for exacerbation of COPD. Randomised controlled trials are proposed to determine whether S. maltophilia should be the target of antibiotic treatment.

Introduction

Stenotrophomonas maltophilia is an ubiquitous, aerobic, non-fermentative, Gram-negative bacillus, first discovered in 1943 [1]. S. maltophilia is an important nosocomial pathogen associated with crude mortality in the hospitalised ranging between 14 and 69% [2] with an attributable mortality rate of up to 37.5% [3].

The role of S. maltophilia in patients with chronic obstructive pulmonary disease (COPD) is poorly understood, and it is debated whether S. maltophilia should be considered a marker of pulmonary disease progression or regarded as a pathogen [4]. However, a recent case report suggested S. maltophilia may be a driver of exacerbation in a patient with COPD [5].

In a Canadian population of COPD outpatients, S. maltophilia was found in 10% of patients, and associated with a 2-fold increase in mortality [6]. However, the sample size was small (n = 397), and the prevalence was notably higher than earlier findings of 0.5% in stable COPD patients [7].

In patients with non-cystic fibrosis bronchiectasis the presence of S. maltophilia is associated with more severe bronchiectasis and more pronounced airway inflammation [8], the same pattern which is seen in patients with cystic fibrosis bronchiectasis [9].

A similar, opportunistic bacterium of the same class of Gammaproteobacteria which has been studied in greater detail, is Pseudomonas aeruginosa. Our group has previously shown that Pseudomonas aeruginosa in patients with COPD was associated with a 3-fold increased risk of acute exacerbations and a highly increased risk of death which is in line with other studies [10] [11, 12]. Likewise, the presence of P. aeruginosa was associated with an increased airway inflammation, more frequent exacerbations and death both in patients with non-cystic fibrosis bronchiectasis [13, 14] as well as patients with cystic fibrosis bronchiectasis [4, 15, 16].

The aim of this study was to determine, in a large cohort of outpatients with COPD with complete follow-up on both outcomes, whether acquiring a lower respiratory tract culture with S. maltophilia was associated with increased mortality and hospitalisation for exacerbation of COPD.

Methods

Data sources

Data were collected from the following databases:

  1. 1.

    The Danish Register of COPD (DrCOPD) is a nationwide register on all COPD patients at all outpatient visits and all hospital-based respiratory outpatient clinics since 2010 [17]. Patients in DrCOPD have been assessed by a pulmonologist and have a spirometry verified diagnosis of COPD. At each outpatient visit a registered nurse performed spirometry, including measurements of forced expiratory volume in one second percent of predicted (FEV1, also expressed as percentage of predicted) and obtained information on Medical Research Council dyspnoea score, body mass index (BMI), and tobacco exposure.

  2. 2.

    The Danish National Patient Registry contains data on all hospital contacts since 1995, including diagnoses and length of contact [18]. Data on co-morbidities, together with hospitalizations due to exacerbations during the study period were obtained from this registry.

  3. 3.

    The Danish National Database of Reimbursed Prescriptions is a nationwide register and includes information on the strength, dose, product name, and Anatomical Therapeutic Chemical classification of each prescription on all redeemed prescriptions [19]. Filled, and reimbursed, prescriptions on inhaled corticosteroids and oral corticosteroids were gathered from this database.

  4. 4.

    Microbiological data from the Clinical Microbiology Departments in Eastern Denmark (Region Zealand and Capital Region) consisting of approximately 2.6 million inhabitants. The register contains information on all microbiological samples, including lower respiratory tract cultures, and by that used to identify patients with S. maltophilia.

Study design

This was a retrospective, registry-based cohort study. The study cohort comprised all COPD patients registered with an outpatient clinic visit in eastern Denmark from 1st January 2010 to 31st October 2017 in DrCOPD. Patients not resident in Eastern Denmark were excluded as we had no access to microbiological data on these patients.

We excluded patients with a history of immunodeficiency (International classification of Diseases 10th revision (ICD-10): D80-D84, D89) and malignancy (ICD-10: C00-C97, except C44) within the last five years from cohort entry, except for non-melanoma malignancies of the skin. Also, patients with a lower respiratory tract sample positive for S. maltophilia within 365 days of cohort entry were excluded to avoid differential misclassification.

Cohort entry was defined as the date for the patient’s first outpatient clinic visit recorded in DrCOPD and only stable patients without hospital admission on the date were included. Patients with only in-hospital registrations were excluded since these registrations do not contain information on essential patient characteristics.

Sputum samples were not taken routinely on all patients, but rather when relevant symptoms were present such as cough, phlegm, dyspnoea, fever etc.

Patients were followed for five years or until the first of either (1) end of follow-up on 1st July 2018, or (2) death.

Statistical analyses

Descriptive statistics were performed on the baseline data at the time of study entry. Comparison between baseline data was performed with a Chi-squared test for categorical data and t test for continuous data.

The hazard ratio of death following a lower respiratory tract culture with S. maltophilia was estimated using a Cox proportional hazards regression. Presence of S. maltophilia was treated as a time-varying exposure, where patients were considered exposed from the time of the first isolation of S. maltophilia in lower respiratory tract samples and for the remainder of the follow-up time, since we could not validly define the patient as having cleared the bacteria. The model was adjusted for the following confounders: age (continuous [year]), FEV1 (continuous [%]), BMI (continuous [kg/m2]), sex (male vs. female), smoking status (active vs. former), severe exacerbations (ICD-10: J44.1) 365 days prior to cohort entry (none, 1, ≥ 2), cumulated dose of budesonide-equivalent ICS 365 days prior to cohort entry (none, ≤ 400 µg, 400–800 µg, > 800 µg), cumulated dose of oral corticosteroids 365 days prior to cohort entry (none, ≤ 250 mg prednisolone, > 250 mg prednisolone), and calendar year for entry in DrCOPD. Cut-off for prednisolone was chosen to reflect a history of exacerbations with “low dose” corresponding to one exacerbation and “high dose” corresponding to two or more exacerbations.

Results are presented as hazard ratios (HR) with 95% confidence intervals (CI) and p-values (P). To assess robustness of the methodology, a propensity score weighted Cox proportional hazards regression was performed as a sensitivity analysis using the same confounders for propensity scoring as was used for adjustment in the Cox proportional hazards regression.

Analysis of the association between acute exacerbations of COPD and a lower respiratory tract culture with S. maltophilia was performed with recurrent event Cox proportional hazards regression analysis using an Andersen-Gill model [20] with death included as a censoring event, adjusting for the same confounders as in the primary analyses.

As sensitivity analyses we performed both a complete case Cox proportional hazards regression and a propensity scoreweighted Cox proportional hazards regression in addition to a self-controlled case series [21], including only the patients with a lower respiratory tract culture with S. maltophilia, they were followed from one year prior to first lower respiratory tract sample positive for S. maltophilia and one year after. Results are presented as incidence rate ratios (IRR) with 95% CI.

Model validation

The proportional hazards assumption was tested by including a test for interaction with time. Additionally, we tested for linearity of the continuous covariates. Continuous covariates that did not meet the criteria for linearity were handled using penalised splines. Missing data were handled by the substantive model for multiple imputation, with 100 imputations with each 20 iterations [22].

Data management and statistical analyses were performed using Statistical Analysis Software 9.4 (SAS Institute, Cary, NC, USA). Multiple imputation, Cox proportional hazards regression, and inverse probability of treatment weighting were completed in R 4.1.3 (R Foundation for Statistical Computing, Vienna, Austria) with the SCCS 1.6, SMCFCS 1.6.1, MITOOLS 2.4, and SURVIVAL 3.3.1 packages respectively.

Results

A total of 106,560 patients with COPD were identified in DrCOPD. Of these 57,843 had at least one outpatient visit during the study period. Patients from Western Denmark (n = 32,617) were excluded due to no accessible microbiological data. Additionally, patients with a diagnosis of malignant disease (n = 2,312) or immunodeficiency (n = 68) within five years before study entry were excluded, as well as those with a lower respiratory tract sample positive for S. maltophilia (n = 89) within 365 days prior potential cohort entry were excluded.

The final study cohort comprised 22,869 patients that contributed with 81,967 person-years of risk time for the analysis. A positive lower respiratory tract sample with S. maltophilia was found in 459 (2.0%) patients (Fig. 1), with median time to first isolation being 673 days (interquartile range: 302–1184 days). Of the 459 patients, 179 (39%) patients had a follow-up respiratory tract sample positive for S. maltophilia. In the remaining 280 (61%) patients S. maltophilia was not found after the initial isolation – 47 (17%) patients had a follow-up respiratory tract sample negative for S. maltophilia, while 223 (83%) patients had no recorded follow-up respiratory tract sample. A total of 7,649 deaths (S. maltophilia positive: 243 (52.9%) and S. maltophilia negative: 7,406 (34.4%)) and 24,912 hospitalisations for exacerbation of COPD (S. maltophilia positive: 1,100 in 459 patients and S. maltophilia negative: 23,821 in 22,230 patients) were registered during the study period. For baseline characteristics see Table 1, and definitions of comorbidities see Supplemental Appendix 1.

Fig. 1
figure 1

Study flowchart. DrCOPD: Danish register of COPD.

Full size image
Table 1 Baseline characteristics at study entry of COPD outpatients with samples positive or negative for S. maltophilia
Full size table

The adjusted Cox proportional hazards regression showed an increased hazard of death: HR 2.6 (95% CI 2.2–3.1, P < 0.0001) and hospitalisation for exacerbation: HR 2.7 (95% CI 2.3–3.1, P < 0.0001) following a positive lower respiratory tract sample for S. maltophilia which were an attenuation of the unadjusted results (Table 2; Figs. 2 and 3. For full adjusted analysis Supplemental Appendix 2). The complete case Cox proportional hazards regression did not change the findings.

Table 2 Hazard for death or hospitalisation with exacerbation of COPD with acquisition of S. maltophilia
Full size table
Fig. 2
figure 2

Simon-Makuch plot of overall survival five years from first outpatient clinic visit according to S. maltophilia status in lower respiratory tract sample (red: sample positive for S. maltophilia and blue: no sample/sample not positive for S. maltophilia. Mean in solid, 95% confidence interval in transparent)

Full size image
Fig. 3
figure 3

Cumulative incidence of hospitalisation of exacerbation of COPD five years from first outpatient clinic visit according to S. maltophilia status in lower respiratory tract samples (red: sample positive for S. maltophilia and blue: no sample/sample not positive for S. maltophilia. Mean in solid, 95% confidence interval in transparent)

Full size image

The PS weighted sensitivity analysis confirmed the main finding: HR for death 3.7 (95% CI 3.1–4.3, P < 0.0001) and HR for hospitalisation 3.3(95% CI 2.7–3.7, P < 0.0001).

Additionally, a self-controlled case series analysis was performed as a further sensitivity analysis on the hospitalisation outcome, which slightly attenuated the finding: IRR 1.8, (95% CI 1.4–2.2, P < 0.0001).

Of the included patients, 19,757 (87%) had complete data on all data variables. The remaining 2,932 (13%) had one or more clinical values missing from the outpatient clinic visit. Most patients with missing data had no data on either FEV1, BMI, and smoking status.

Discussion

In this registry-based cohort study of outpatients with COPD we found that a lower respiratory tract sample positive for S. maltophilia was strongly and independently associated with a marked increase in mortality as well as hospitalisation for exacerbation of COPD, both results robust for adjustment and sensitivity analysis.

The evidence on COPD and the role of S. maltophilia is sparse. A Canadian study screened all COPD patients on their visits to the respiratory outpatient clinic and found a sputum sample positive for S. maltophilia in 10%. S. maltophilia was associated with a 2-fold increase in mortality, however, the sample size was small (n = 397) and notably the prevalence of S. maltophilia (10%) was markedly higher than earlier findings in stable COPD patients including in the present study (0.5-2.0%) [7]. Also, no other clinical outcomes were reported. Interestingly, even with 15% having a malignant diagnosis, the mortality rate during mean follow-up of 2 years (S. maltophilia: 22%, controls: 7%) was notably lower than in our study (S. maltophilia: 60%, controls: 20%) while base line data were similar. The two year mortality rate of COPD patients have previously been reported to be 16% in stable COPD patients [23] increasing to 35–55% in COPD patients following hospitalisation for exacerbation [24, 25].

In other chronic pulmonary diseases, S. maltophilia in the lower respiratory tract has been associated with deteriorating clinical end points. A recent study investigating the sputum microbiome and clinical outcomes in patients with bronchiectasis showed that S. maltophilia was associated with more severe bronchiectasis and a higher degree of lung inflammation [8]. In patients with cystic fibrosis bronchiectasis, S. maltophilia is a well-established contributor to irreversible decline in lung function and increase in exacerbations [15, 16]. The pathogenesis is closely linked to well-studied and complex virulence mechanisms, cross-infection, and multi-resistance [4].

Strengths of the current study include observations based on a large and well-characterized population of patients with a respiratory specialist verified and spirometry confirmed diagnosis of COPD. The patients had two or more outpatient clinic visits but were, in all other aspects, unselected, likely reducing the risk of bias. Further, our registries contain data on many important confounders such as smoking status, oral and inhaled corticosteroid use, FEV1, and BMI, allowing us to account for all these, and the completeness of these data was high. The exposure, a lower respiratory tract sample positive for S. maltophilia, was well established for the entire cohort, as we had access to all microbiological data from Eastern Denmark during the entire study period. This included all samples cultured from admitted patients, outpatients, emergency department visits and primary care. Last, there was a 100% follow-up on death and hospital admission for exacerbation for COPD which in combination with a large sample size (n = 22,869) minimize the risk of false positive results.

Despite the noted strengths, our study has some important limitations that deserve careful considerations. Firstly, we do not have lower respiratory tract samples from all patients. In our outpatient clinics, it is custom, and described in national guidelines, that all COPD patients with symptoms suggesting an airway infection shall be culture sampled. Accordingly, we do not have follow-up lower respiratory tract samples from approximately half the patients positive for S. maltophilia. However, most of the patients who did have a follow-up sample available, 79% remained positive for S maltophilia. Secondly, we do not hold data on previous non-hospital requiring exacerbations of COPD, but we account for this by controlling for oral corticosteroid use as a proxy for exacerbations.

In conclusion, we present a large and population-based dataset from patients with COPD regarding S. maltophilia and clinical events. We show, in an unselected, well-characterised, Danish population of COPD outpatients, that a lower respiratory tract sample positive for S. maltophilia is associated with a substantial increase in mortality and hospitalisation for exacerbation of COPD. These results were robust to multiple sensitivity analyses and seem biologically plausible. Clinicians should be aware of this pathogen as a possible cause, or at least marker, of clinical decline and events. Randomised controlled trials in which patients with such a positive culture are allocated to a relevant antibiotic therapy or placebo, are strongly encouraged.

Data availability

The data supporting the findings of this study are available from The Danish Health Data Authority following application and approval from The Danish Health Authority. Restrictions apply to the availability of these data, which were used under the license for this study.

References

  1. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998;11(1):57–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012;25(1):2–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Falagas ME, Kastoris AC, Vouloumanou EK, et al. Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature. Future Microbiol. 2009;4(9):1103–9.

    Article  PubMed  Google Scholar 

  4. Hansen CR. Stenotrophomonas maltophilia: to be or not to be a cystic fibrosis pathogen. Curr Opin Pulm Med. 2012;18(6):628–31.

    Article  PubMed  Google Scholar 

  5. Oladunjoye OO, Oladunjoye AO, Oladiran O, et al. Stenotrophomonas maltophilia infection in a patient with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD): a colonizer or true infection? Am J Case Rep. 2020;21:e924577.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Soumagne T, Levesque F, Milot J, et al. Significance of Stenotrophomonas maltophilia when detected in Sputum of ambulatory patients with COPD. Int J Chron Obstruct Pulmon Dis. 2021;16:2895–900.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Soler N, Ewig S, Torres A, et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J. 1999;14(5):1015–22.

    Article  CAS  PubMed  Google Scholar 

  8. Dicker AJ, Lonergan M, Keir HR, et al. The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study. The Lancet Respiratory Medicine. 2021;9(8):885–96.

    Article  CAS  PubMed  Google Scholar 

  9. Barsky EE, Williams KA, Priebe GP, et al. Incident Stenotrophomonas maltophilia infection and lung function decline in cystic fibrosis. Pediatr Pulmonol. 2017;52(10):1276–82.

    Article  PubMed  Google Scholar 

  10. Eklöf J, Sørensen R, Ingebrigtsen TS, et al. Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22 053 patients. Clin Microbiol Infect. 2020;26(2):227–34.

    Article  PubMed  Google Scholar 

  11. Jacobs DM, Ochs-Balcom HM, Noyes K, et al. Impact of Pseudomonas aeruginosa isolation on Mortality and Outcomes in an Outpatient Chronic Obstructive Pulmonary Disease Cohort. Open Forum Infect Dis. 2020;7(1):ofz546.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Renom F, Yáñez A, Garau M, et al. Prognosis of COPD patients requiring frequent hospitalization: role of airway infection. Respir Med. 2010;104(6):840–8.

    Article  PubMed  Google Scholar 

  13. Goeminne PC, Nawrot TS, Ruttens D, et al. Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir Med. 2014;108(2):287–96.

    Article  CAS  PubMed  Google Scholar 

  14. Rogers GB, Zain NMM, Bruce KD, et al. A Novel Microbiota Stratification System predicts future exacerbations in Bronchiectasis. Annals of the American Thoracic Society. 2014;11(4):496–503.

    Article  PubMed  Google Scholar 

  15. Lenney W. Pseudomonas aeruginosa in cystic fibrosis is potentially serious, and more than merely a marker for disease severity. Paediatr Respir Rev. 2015;16(Suppl 1):35–6.

    PubMed  Google Scholar 

  16. Folkesson A, Jelsbak L, Yang L, et al. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat Rev Microbiol. 2012;10(12):841–51.

    Article  CAS  PubMed  Google Scholar 

  17. Lange P, Tøttenborg SS, Sorknæs AD, et al. Danish Register of chronic obstructive pulmonary disease. Clin Epidemiol. 2016;8:673.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Lynge E, Sandegaard JL, Rebolj M. The danish National Patient Register. Scand J Public Health. 2011;39(7 Suppl):30–3.

    Article  PubMed  Google Scholar 

  19. Johannesdottir SA, Horváth-Puhó E, Ehrenstein V, et al. Existing data sources for clinical epidemiology: the danish National Database of reimbursed prescriptions. Clin Epidemiol. 2012;4:303–13.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Andersen PK, Gill RD. Cox’s regression model for counting processes: a large sample study. The Annals of Statistics. 1982;10(4):1100–20.

    Article  Google Scholar 

  21. Whitaker HJ, Paddy Farrington C, Spiessens B, et al. Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2006;25(10):1768–97.

    Article  PubMed  Google Scholar 

  22. Bartlett JW, Seaman SR, White IR, et al. Multiple imputation of covariates by fully conditional specification: accommodating the substantive model. Stat Methods Med Res. 2015;24(4):462–87.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Maters GA, de Voogd JN, Sanderman R, et al. Predictors of all-cause mortality in patients with stable COPD: medical co-morbid conditions or high depressive symptoms. COPD: J Chronic Obstr Pulmonary Disease. 2014;11(4):468–74.

    Article  Google Scholar 

  24. Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–63.

    Article  PubMed  Google Scholar 

  25. Peltola L, Pätsi H, Harju T. COPD Comorbidities Predict High mortality – Asthma-COPD-Overlap has better prognosis. COPD: J Chronic Obstr Pulmonary Disease. 2020;17(4):366–72.

    Article  Google Scholar 

Download references

Funding

The study was financed by grants from the Novo Nordisk Foundation (No. NNF20OC0060657). The funding sources had no influence on study design, data collection, analysis, or reporting of data.

Open access funding provided by Royal Library, Copenhagen University Library

Author information

Authors and Affiliations

  1. Section of Respiratory Medicine, Department of Medicine, Copenhagen University Hospital – Gentofte, Hellerup, Denmark

    Christian Rønn, Peter Kamstrup, Josefin Eklöf, Louise Lindhardt Toennesen, Jon Torgny Wilcke, Pradeesh Sivapalan & Jens-Ulrik Stæhr Jensen

  2. Department of Clinical Microbiology, Copenhagen University Hospital - Herlev, Herlev, Denmark

    Jonas Bredtoft Boel

  3. Department of Clinical Microbiology, Copenhagen University Hospital - Hvidovre, Hvidovre, Denmark

    Christian Ostergaard Andersen

  4. Department of Clinical Microbiology, Zealand University Hospital, Slagelse, Denmark

    Ram Benny Dessau

  5. Department of Regional Health Research, University of Southern Denmark, Odense, Denmark

    Ram Benny Dessau

  6. Department of Respiratory Medicine, Copenhagen University Hospital - Hvidovre, Hvidovre, Denmark

    Charlotte Suppli Ulrik

  7. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

    Charlotte Suppli Ulrik & Jens-Ulrik Stæhr Jensen

Authors
  1. Christian Rønn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Kamstrup
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Josefin Eklöf
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Louise Lindhardt Toennesen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jonas Bredtoft Boel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christian Ostergaard Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ram Benny Dessau
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jon Torgny Wilcke
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Pradeesh Sivapalan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Charlotte Suppli Ulrik
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jens-Ulrik Stæhr Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: CR, PS, JE, CSU, and JUSJ; Methodology: All authors; Software: CR and PK; Formal analysis: CR and PK; Resources: JUSJ; Data Curation: CR and PK; Writing – original draft preparation: CR, PK, PS, JE, CSU, and JUSJ; Writing – review and editing: CR, PK, JE, LLT, JBB, COA, RBD, JTW, PS, CSU, and JUSJ; Visualization: CR; Supervision: PS, CSU, and JUSJ; Project Administration: CR, PS, JE, CSU, and JUSJ; Funding acquisition: JUSJ. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Christian Rønn.

Ethics declarations

Competing interests

Outside the submitted work: RBD has been on a advisory board for Pfizer. CSU has received grants from Sanofi, Boehringer Ingelheim, AstraZeneca, and Novartis, consulting fees from Chiesi, Orion Pharma, AstraZeneca, GSK, and TEVA,speaker fees from Orion Pharma, AstraZeneca, and TEVA, and been on advisory boards for Novartis, Sanofi, Glaxo-Smith Kline, Chiesi, AstraZeneca, and Boehringer Ingelheim.

Ethics approval and consent to participate

In Denmark retrospective use of registry data does not require patient consent nor approval from the Danish National Committee on Health Research Ethics.

Consent for publication

Not applicable.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rønn, C., Kamstrup, P., Eklöf, J. et al. Mortality and exacerbations associated with Stenotrophomonas maltophilia in chronic obstructive pulmonary disease. A regional cohort study of 22,689 outpatients. Respir Res 24, 232 (2023). https://doi.org/10.1186/s12931-023-02544-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12931-023-02544-w

Respiratory Research

ISSN: 1465-993X

Contact us